Abstract: Abstract: Objective To investigate the change of serum CA724, CA242 and AFP levels before and after transcatheter
artery chemoembolization (TACE) treatment of primary hepatic carcinoma（PHC）patients as well as its clinic significance.
Methods Patients of PHC (n=45) and healthy adults (n=40) were enrolled. Serum samples were collected from each healthy
people and PHC patients 2 days before TACE， l week and 1 month after TACE. Electrochemiluminescence Immunoassay (ECLI)
was used to determine serum CA724, CA242 and AFP levels, and correlations among three indexes as well as their relationships
with clinical data were also analysed., Change of serum CA724 and CA242 levels before and after TACE were compared in AFP <
400 μg/L group and AFP≥400 μg/L group. Results Serum levels of CA724, CA242 and AFP in PHC group were significantly
higher than that in healthy control groups before TACE therapy（P < 0.05） . Positive rates of serum CA724 and AFP were higher
in PHC group（P < 0.01） than that in healthy control group. AFP decreased significantly at both 1 week and 1 month upon TACE
treatment compared with that at before teratment（P < 0.01） . CA724 was significantly lower at one month after treatment than that
at before treatment（P < 0.05） . But there was no significant difference in CA242 before and after treatment（P > 0.05） . CA724
and AFP expressions are associated with tumor size（P < 0.05） . After one month of therapy, serum CA724 level was obviously
decreased in both AFP <400 μg/L and AFP≥400 μg/L groups. Before and after TACE therapy, there was a positive correlation
between the expression of AFP and CA724 （r=0.754， P < 0.05） . Conclusion Serum CA724 can be used as one of the tumor
markers to assist the evaluation of curative effect of TACE on PHC.

Key words: liver neoplasms, neoplasms, multiple primary, alpha-fetoproteins, CA724, CA242, TACE